VISIPAQUE SUMMARY
VISIPAQUE™
(iodixanol) Injection
320
VISIPAQUE™ (iodixanol) Injection, 5,5'-[(2-hydroxy-1,3-propanediyl)bis (acetylimino)]bis[N,N'-bis(2,3-dihydroxypropyl)-2,4,6- triiodo-1,3- benzenedicarboxamide], is a dimeric, isosmolar, nonionic, water-soluble, radiographic contrast medium with a molecular weight of 1550.
INTRA-ARTERIAL
VISIPAQUE Injection (270 mgI/mL) is indicated for intra-arterial digital subtraction angiography.
VISIPAQUE Injection (320 mgI/mL) is indicated for angiocardiography (left ventriculography and selective coronary arteriography), peripheral arteriography, visceral arteriography, and cerebral arteriography.
INTRAVENOUS For information on the concentrations and doses for the pediatric population see the Precautions–Pediatric Use, Clinical Pharmacology–Special Populations, and Dosage and Administration sections.
VISIPAQUE Injection (270 mgI/mL) is indicated for CECT imaging of the head and body, excretory urography, and peripheral venography.
VISIPAQUE Injection (320 mgI/mL) is indicated for CECT imaging of the head and body, and excretory urography.
|
VISIPAQUE NEWS HIGHLIGHTS Media Articles Related to Visipaque (Iodine Intravascular)
Michelson Diagnostics To Demonstrate Prototype Hand-Held OCT Probe At BIOS 09
Source: Dermatology News From Medical News Today [2008.11.19]
AspenBio Pharma Reports On FDA 510(k) Clinical Trial Progress For AppyScore, World's First Blood-Based Diagnostic Test For Human Appendicitis
Source: Blood / Hematology News From Medical News Today [2008.11.18]
The Future For Medical Diagnostics Is Gold Nanostars
Source: Water - Air Quality / Agriculture News From Medical News Today [2008.11.09]
Cepheid Molecular Diagnostic Test For Positive Blood Culture Bottles Categorized 'Moderate Complexity' By FDA
Source: MRSA / Drug Resistance News From Medical News Today [2008.11.05]
PSA Test Losing Diagnostic Value, Study Says
Source: MedicineNet Prostate Specific Antigen Specialty [2008.03.11]
Published Studies Related to Visipaque (Iodine Intravascular)
Renal toxicity evaluation and comparison between visipaque (iodixanol) and hexabrix (ioxaglate) in patients with renal insufficiency undergoing coronary angiography: the RECOVER study: a randomized controlled trial. [2006.09.05]
Intravenous contrast material administration at helical 16-detector row CT coronary angiography: effect of iodine concentration on vascular attenuation. [2005.08]
Nephrotoxicity of iodixanol versus ioversol in patients with chronic kidney disease: the Visipaque Angiography/Interventions with Laboratory Outcomes in Renal Insufficiency (VALOR) Trial. [2008.10]
Comparison between gadolinium and iodine contrast for percutaneous intervention in atherosclerotic renal artery stenosis: clinical outcomes. [2008.04]
MDCT angiography for detection of pulmonary emboli: Comparison between equi-iodine doses of iomeprol 400mgI/mL and iodixanol 320mgI/mL. [2008.03.31]
Clinical Trials Related to Visipaque (Iodine Intravascular)
RECOVER:Comparison of Renal Toxicity Between Visipaque(Iodixanol)and Hexabrix(Ioxaglate)in Renal Insufficiency Undergoing Coronary Angiography [Completed]
Pilot Study to Compare ISOVUE®-250 and VISIPAQUEâ„¢ 270 for Motion Artifact and Pain in Peripheral (DSA) [Recruiting]
Iodixanol vs. Iomeprol to Prevent Contrast-Induced Nephropathy After Coronary Intervention (CONTRAST) [Active, not recruiting]
Renal Safety Following the Intra-Arterial Administration of Iopamidol vs. Iodixanol During Coronary Angiography in Diabetic Patients [Not yet recruiting]
Study in Subjects Suspected of Having CAD Undergoing VISIPAQUE-Enhanced CCTA as Part of Their Routine Medical Care [Recruiting]
|
